Expanding Precision Oncology

With precision medicine, doctors tailor treatment to the molecular features of a person’s cancer. MSK scientists have identified hundreds of cancer-related mutations, proteins, and other traits, and pioneered new targeted therapies that take aim at them.

Support precision medicine programs

Three MSK experts standing in a lab, facing the camera and smiling

Pinpointing molecular drivers of cancer today

Researchers in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology examine the molecular features of tumors.
MSK-IMPACT® detects 500-plus genes with cancer-related mutations and is used to match patients with targeted therapies.
MSK-ACCESS® is a liquid biopsy test used to noninvasively diagnose cancer recurrence.
MSK created the OncoKB® database to track which mutations are most clinically relevant for each kind of cancer.

To develop targeted drugs that give patients more tomorrows

The discovery of molecular drivers of cancer has revolutionized targeted therapies, which are changing, enhancing, and extending lives around the world. MSK laid the foundation for a future in which profound molecular insights can lead to powerful new therapies and the next generation of precision medicine tools.

A young girl wearing pigtails with white bows, a white top, tan shorts, and a pink backpack holds the hand of an older woman and smiles.

Rihanna was born with a large sarcoma on her right arm. After testing the tumor, doctors found a genetic mutation and were able to give her the targeted therapy larotrectinib (Vitrakvi®).

Three people sit, smiling, on a marble bench, with greenery behind them. From left: an older man, a middle-aged man, and a teenage boy.

MSK-IMPACT testing revealed a hereditary cancer gene affecting (from left) Lenny, Judah, and Michael Deutsch. All three continue to be monitored.

A young woman wearing a red top and jeans is standing outside, leaning against a fence and smiling.

Giovanna Whitting was running out of treatment options for metastatic thyroid cancer. MSK doctors matched her with a drug that takes aim at the mutation that was driving her cancer. It worked, enabling her to live a cancer-free life.

See how your gift can propel precision oncology

Support lab-to-clinic research

Through a transformative $100 million gift, longtime donors Fiona and Stanley Druckenmiller are supporting promising translational research at MSK through the Fiona and Stanley Druckenmiller Presidential Innovation Fund.

Learn what donors can do